Literature DB >> 18607963

Intratympanic gentamicin therapy for control of vertigo in unilateral Menire's disease: a prospective, double-blind, randomized, placebo-controlled trial.

Rolf J Postema1, Charlotte M Kingma, Hero P Wit, Frans W J Albers, Bernard F A M Van Der Laan.   

Abstract

CONCLUSIONS: Intratympanic application of gentamicin is a relatively safe and efficient treatment for the reduction of complaints of vertigo attacks associated with Menière's disease. The treatment also reduces the severity of the perceived aural fullness.
OBJECTIVE: To investigate the effectiveness of intratympanic gentamicin treatment in patients with unilateral Menière's disease. SUBJECTS AND METHODS: In a prospective, double-blind, randomized, placebo-controlled clinical trial subjects scored vertigo complaints, aural fullness and tinnitus, before, during and up to 1 year after treatment. Hearing loss was monitored with pure tone audiometry.
RESULTS: Gentamicin treatment resulted in a significant reduction of the score for vertigo complaints and the score for perceived aural fullness. A small increase in hearing loss (average 8 dB) was measured in the gentamicin group.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18607963     DOI: 10.1080/00016480701762458

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  14 in total

Review 1.  Menière's disease.

Authors:  Tony Wright
Journal:  BMJ Clin Evid       Date:  2015-11-05

2.  Uptake of gentamicin by vestibular efferent neurons and superior olivary complex after transtympanic administration in guinea pigs.

Authors:  Yi-Bo Zhang; Ru Zhang; Wei-Feng Zhang; Peter S Steyger; Chun-Fu Dai
Journal:  Hear Res       Date:  2011-10-31       Impact factor: 3.208

Review 3.  The treatment and natural course of peripheral and central vertigo.

Authors:  Michael Strupp; Marianne Dieterich; Thomas Brandt
Journal:  Dtsch Arztebl Int       Date:  2013-07-22       Impact factor: 5.594

4.  MR volumetric assessment of endolymphatic hydrops.

Authors:  R Gürkov; A Berman; O Dietrich; W Flatz; C Jerin; E Krause; D Keeser; B Ertl-Wagner
Journal:  Eur Radiol       Date:  2014-10-16       Impact factor: 5.315

5.  The effect of intratympanic gentamicin for treatment of Ménière's disease on lower frequency hearing.

Authors:  Gerben Sam; Dick Wong Chung; Ruud van der Hoeven; Sjoerd Verweij; Matthijs Becker
Journal:  Int J Clin Pharm       Date:  2016-04-12

6.  Treatment of Menière's Disease.

Authors:  Jeffrey D Sharon; Carolina Trevino; Michael C Schubert; John P Carey
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

7.  Low Dose Intratympanic Gentamicin in Ménière's Disease.

Authors:  Bini Faizal; Afsha Rajan
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-09-01

Review 8.  [Peripheral, central and functional vertigo syndromes].

Authors:  M Strupp; M Dieterich; A Zwergal; T Brandt
Journal:  Nervenarzt       Date:  2015-12       Impact factor: 1.214

9.  Intratympanic (IT) Therapies for Menière's Disease: Some Consensus Among the Confusion.

Authors:  Desi P Schoo; Grace X Tan; Matthew R Ehrenburg; Seth E Pross; Bryan K Ward; John P Carey
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-05-03

Review 10.  Effects of intratympanic gentamicin and intratympanic glucocorticoids in Ménière's disease: a network meta-analysis.

Authors:  Weiming Hao; Huiqian Yu; Huawei Li
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.